IONQ Inc vs Revolution Medicines Inc. Common Stock — how do they compare? IONQ Inc trades at $39.34 (market cap $15.98B), while Revolution Medicines Inc. Common Stock trades at $191.91 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 2.5× IONQ Inc's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| IONQ | RVMD | |
|---|---|---|
Market Cap | $15.98B | $40.32B |
Volume | 22,848,240 | 4,855,734 |
Sector | Technology | Health |
52-Week High | $82.09 | $221.15 |
52-Week Low | $26.59 | $47.50 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $13.92B | $37.02B |
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.19, down 5.2% in the last session, with a bearish technical outlook despite recent positive analyst coverage. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a net income margin of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss following two consecutive beats. The stock remains 50% below analyst consensus price target of $62.75, indicating substantial upside potential if execution improves.
IONQ presents a high-risk, high-reward opportunity with Wall Street divided (50% buy, 50% hold). The bullish case hinges on quantum computing leadership and partnerships with major cloud providers, while risks include persistent losses, cash burn, and execution challenges in a nascent market. Current valuation metrics (P/S: 54.74) reflect growth expectations rather than current fundamentals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →